A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy

PURPOSE: To establish the safety, tolerability, pharmacokinetics, and pharmacodynamics of an intravitreal injection of recombinant human complement factor H (CFH), GEM103, in individuals with genetically defined age-related macular degeneration (AMD) and geographic atrophy (GA). DESIGN: Phase I sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanani, Arshad M., Maturi, Raj K., Bagheri, Nika, Bakall, Benjamin, Boyer, David S., Couvillion, Stephen S., Dhoot, Dilsher S., Holekamp, Nancy M., Jamal, Karim N., Marcus, Dennis M., Pieramici, Dante, Aziz, Aamir A., Patki, Kiran C., Bridges, William Z., Barone, Samuel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559901/
https://www.ncbi.nlm.nih.gov/pubmed/36249705
http://dx.doi.org/10.1016/j.xops.2022.100154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559901/
https://www.ncbi.nlm.nih.gov/pubmed/36249705
http://dx.doi.org/10.1016/j.xops.2022.100154

Ejemplares similares